TreatmentTrends , Multiple Sclerosis Study Uncovers Early Impact Of Gilenya
 

BioTrends recently published TreatmentTrends: Multiple Sclerosis, a syndicated biannual report that provides a comprehensive view of the current and expected future management of multiple sclerosis based on primary research fielded with 103 neurologists in the U.S. A parallel report covering the European market will be published later this month.



More...

(From Topix Neurology)

"Gilenya treats the relapsing form of MS. The drug significantly reduces MS attacks. However, it has serious side effects, with possible heart, lung, and eye toxicity and increased risk of infection. Patients must be closely monitored, and regular eye exams are advised."